CD274 and cancer: A pan-cancer study indicated that TMB-high status predicts response to anti-PD-1 therapy, independent of PD-L1 status, attesting to the independent predictive value of these biomarkers55,56 and suggesting that GAs associated with TMB-high status may have clinical relevance.